In reference to the e-mail regarding Discrepancy in Financial Results submitted for the Half Year ended September 2017 under Reg. 33(3)(b) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 dated November 21, 2017, ANG Lifesciences India has informed about the bifurcation of Trade payables as per Schedule III of Companies Act, 2013 in Statement of Assets & Liability.
The above information is a part of company’s filings submitted to BSE.